Skip To Main Content
Y. S. Babu on Muck Rack

Y. S. Babu

As seen in: AIChE Journal, Color Research & Application, The Journal of Biological Chemistry
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Y. S. Babu’s profile

Articles by Y. S. Babu

Intracellular rebinding of transition-state analogues provides extended in vivo inhibition lifetimes on human purine nucleoside phosphorylase

|
By Sara T. Gebre, Albert Einstein College, Scott Cameron Verified, Y. S. Babu
| The Journal of Biological Chemistry Verified
Purine nucleoside phosphorylase (PNP) is part of the human purine salvage pathway. Its deficiency triggers apoptosis of activated T-cells, making it a target for T-cell proliferative disorders. Transition-state analogues of PNP bind with picomolar (pm) dissociation constants. Tight-binding PNP inhibitors show exceptionally long lifetimes on the target enzyme. We solve the mechanism of the target residence time by comparing functional off-rates in vitro and in vivo.
Open in Who Shared Issue with article?

Intracellular rebinding of transition-state analogues provides extended in vivo inhibition lifetimes on human purine nucleoside phosphorylase

|
By Scott Cameron Verified, Y. S. Babu, Vern L. Schramm, Sara T. Gebre
| The Journal of Biological Chemistry Verified
Purine nucleoside phosphorylase (PNP) is part of the human purine salvage pathway. Its deficiency triggers apoptosis of activated T-cells, making it a target for T-cell proliferative disorders. Transition-state analogues of PNP bind with picomolar (pM) dissociation constants. Tight-binding PNP inhibitors show exceptionally long lifetimes on the target enzyme. We solve the mechanism of the target residence time by comparing functional off-rates in vitro and in vivo.
Open in Who Shared Issue with article?

Safety, Pharmacokinetics, and Pharmacodynamics of Avoralstat, an Oral Plasma Kallikrein Inhibitor: Phase 1 Study

|
By R. Paul Wilson, Jian Qiao Zhang, M. Cornpropst, P. Collis, J. Collier, Y. S. Babu, L. Fang, J Zong, W. P. Sheridan
| Allergy - European Journal of Allergy and Clinical Immunology Verified
Avoralstat (n=71) was generally well tolerated with no signals for a safety concern; there were no serious adverse events or discontinuations due to adverse events (AEs), and compared to placebo (n=18), no notable difference in AEs. Four moderate-severity AEs were reported in 2 subjects; syncope after a single 250 mg dose (1 subject) and abdominal pain, back pain, and eczema after multiple doses of 800 mg avoralstat (1 subject).
Open in Who Shared Issue with article?
Show More